News Headlines Article

F.D.A. Backs Respiratory Distress Drug for Babies
New York Times

One of the biotechnology industry’s longest losing streaks ended Tuesday when Discovery Laboratories finally won approval for its first drug, after failing on four previous tries going back to 2004. The Food and Drug Administration approved the drug, Surfaxin, for the prevention of respiratory distress syndrome, a potentially fatal breathing disorder affecting premature babies.